Aldeyra Therapeutics, Inc.(ALDX)- NASDAQ
  • Fri, Sep. 2, 7:26 AM
    • In a regulatory filing, Aldeyra Therapeutics (NASDAQ:ALDX) reports that Chief Operating Officer Scott Young resigned effective August 30 by mutual agreement. The specific reasons for the move are not provided.
    | Fri, Sep. 2, 7:26 AM
  • Wed, Aug. 10, 9:40 AM
    • Aldeyra Therapeutics (ALDX +2.2%) Q2 results: Revenues: $0; R&D Expense: $2.8M (+133.3%); SG&A: $1.5M (+50.0%); Net Loss: ($4.3M) (-95.5%); Loss Per Share: ($0.41) (-51.9%); Quick Assets: $32.5M (+17.8%).
    • No guidance given.
    | Wed, Aug. 10, 9:40 AM
  • Wed, Aug. 10, 7:05 AM
    • Aldeyra Therapeutics (NASDAQ:ALDX): Q2 EPS of -$0.41 beats by $0.03.
    • Cash and cash equivalents of $17.6M
    • Press Release
    | Wed, Aug. 10, 7:05 AM
  • Tue, Aug. 9, 9:19 AM
    | Tue, Aug. 9, 9:19 AM | 2 Comments
  • Fri, Jul. 1, 10:13 AM
    • Aldyra Therapeutics (NASDAQ:ALDX) initiated with Buy rating and $16 (158% upside) price target by Stifel Nicolaus.
    • Shire plc (NASDAQ:SHPG) re-initiated with Buy rating and 6300p (36% upside) price target by Goldman Sachs.
    • Karyopharm Therapeutics (NASDAQ:KPTI) initiated with Outperform rating and $16 (129% upside) price by Baird.
    • Ultragenyx (NASDAQ:RARE) initiated with Buy rating and $72 (41% upside) price target by Bank of America.
    • NantHealth (NASDAQ:NH) initiated with Buy rating and $17 (36% upside) price target by Canaccord Genuity. First Analysis rates it Overweight with an $18 (44% upside) price target. Cowen and Company rates it Outperform with a $19 (52% upside) price target.
    • Clearside Biomedical (Pending:CLSD) initiated with Buy rating and $13 (84% upside) price target by Stifel Nicolaus. Cowen & Company rates it Outperform. Wedbush rates it Outperform with $28 (296% upside) price target.
    • GW Pharmaceuticals (NASDAQ:GWPH) initiated with Sell rating and $40 (57% downside risk) price target by Janney Capital.
    | Fri, Jul. 1, 10:13 AM | 3 Comments
  • Fri, May 27, 6:33 AM
    • Aldeyra Therapeutics(NASDAQ:ALDX) prices its public offering of 2.4M shares of common stock at $5 a share. Underwriters over-allotment is an additional 360K shares. Closing date is June 1.
    • Yesterday's close was $5.44.
    | Fri, May 27, 6:33 AM
  • Thu, May 26, 11:01 AM
    | Thu, May 26, 11:01 AM
  • Thu, May 26, 9:18 AM
    | Thu, May 26, 9:18 AM | 1 Comment
  • Mon, May 9, 9:29 AM
    • Thinly traded nano cap Aldeyra Therapeutics (NASDAQ:ALDX) is up 11% premarket, albeit on only 700 shares, in response to its announcement that lead product candidate, NS2, was comparable to standard-of-care topical ocular corticosteroids in reducing anterior chamber cell count in patients with active anterior noninfectious anterior uveitis in a Phase 2 study.
    • 45 subjects were randomized equally to receive NS2 0.5% four times a day or Pred Forte 1% (corticosteroid) four times a day or NS2 0.5% four times a day and Pred Forte twice daily. There were no statistical differences among all groups in any clinical endpoint. NS2 was generally well-tolerated with no serious adverse events observed.
    • NS2 is an aldehyde-binding molecule or aldehyde trap. By decreasing aldehyde load, it may mitigate excessive inflammation caused by excess aldehydes.
    • Previously: Aldeyra's lead product candidate successful in mid-stage study in allergic conjunctivitis; shares up 38% (Feb. 29)
    | Mon, May 9, 9:29 AM
  • Mon, May 9, 7:33 AM
    | Mon, May 9, 7:33 AM
  • Wed, Mar. 30, 7:34 AM
    • Aldeyra Therapeutics (NASDAQ:ALDX): FY15 EPS of -$1.40
    | Wed, Mar. 30, 7:34 AM
  • Mon, Feb. 29, 12:55 PM
    | Mon, Feb. 29, 12:55 PM
  • Mon, Feb. 29, 7:35 AM
    • Aldeyra Therapeutics (NASDAQ:ALDX) announces positive results in a Phase 2a clinical trial assessing lead product candidate, topical ocular NS2, in subjects with induced allergic conjunctivitis (AC).
    • 100 healthy men and women with at least a two-year history of AC related to grass, tree or ragweed pollen were randomized to receive either NS2 or vehicle. They were then challenged with a conjunctival allergen provocation test (CAPT). Results were measured on a 0-to-4 patient-determined scale of ocular itching and tearing, the two most common inflammation-related symptoms of AC. There was a statistically significant difference in the NS2 cohort compared to vehicle in both ocular itching (p<0.05) and tearing (p<0.05). The effects of NS2 persisted across all time points in the three hours following CAPT challenge despite a stronger-than-anticipated vehicle (placebo) effect.
    • NS2 was well-tolerated with no safety issues observed, although transient and mild stinging was noted in the treatment arm.
    • Data from a Phase 2 study in anterior uveitis should be available in Q2.
    • NS2 is an aldehyde-binding molecule. By decreasing aldehyde load, it may mitigate excessive inflammation caused by excess aldehydes.
    • Management will host a conference call this morning at 8:00 am ET to discuss the data.
    • Update: Shares are up 38% on a 26x surge in volume in early trading.
    | Mon, Feb. 29, 7:35 AM
  • Nov. 12, 2015, 7:34 AM
    • Aldeyra Therapeutics (NASDAQ:ALDX): Q3 EPS of -$0.35 misses by $0.05.
    | Nov. 12, 2015, 7:34 AM
  • Aug. 11, 2015, 7:31 AM
    • Aldeyra Therapeutics (NASDAQ:ALDX): Q2 EPS of -$0.27 beats by $0.08.
    | Aug. 11, 2015, 7:31 AM
  • Jul. 2, 2015, 9:07 AM
    • Onconova (NASDAQ:ONTX) upgraded to Overweight from Neutral with a $6 (131% upside) price target (up from $3) by Piper Jaffray.
    • BioCryst Pharmaceuticals (NASDAQ:BCRX) upgraded to Buy from Neutral with a $19 (30% upside) price target (up from $12) by Bank of America.
    • Kythera Biopharmaceuticals (NASDAQ:KYTH) downgraded to Market Perform from Outperform with a $65 (13% downside risk) price target (up from $61) by Leerink Swann.
    • Zoetis (NYSE:ZTS) downgraded to Market Perform from Outperform with a $57 (18% upside) price target (up from $51) by BMO.
    • China Cord Blood (NYSE:CO) downgraded to Neutral from Buy with a $6.75 (9% upside) price target (up from $6.50) by Roth Capital.
    • Teladoc (Pending:TDOC) initiated with Outperform rating and $35 (23% upside) price target by RBC.
    • Aldeyra (NASDAQ:ALDX) initiated with Buy rating and $16 (93% upside) price target by Canaccord Genuity.
    • Novagen (NASDAQ:NVGN) initiated with Buy rating and $8.50 (89% upside) price target by H.C. Wainwright.
    | Jul. 2, 2015, 9:07 AM | 10 Comments